Sign In

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.


Pantec Biosolutions presents new drug delivery platform and supporting preclinical data

Ruggell, Liechtenstein, 16 January 2008, Pantec Biosolutions AG, a private drug delivery company focused on innovative transdermal delivery of large molecular weight drugs, will present its novel P.L.E.A.S.E® intraepidermal drug delivery platform at the upcoming Drug Delivery Partnerships 2008 conference in San Diego, 21-23 January 2008.

At the drug delivery conference, Pantec will publicly unveil its laser microporation technology P.L.E.A.S.E.®, a hand held drug delivery device for the painless delivery of large molecular weight drugs. P.L.E.A.S.E.® stands for “Painless Laser Epidermal System”.

In its company presentation, Pantec will be discussing the development and production of the most efficient hand held laser microporator of its size, P.L.E.A.S.E.®, and the company’s latest preclinical data, demonstrating the drug delivery platform’s use in the therapeutic areas of In Vitro Fertilisation (IVF), endocrinology and pain.

These achievements have enabled Pantec Biosolutions to implement its clinical strategy for IFV hormone treatment, with the ultimate objective of offering the P.L.E.A.S.E.® platform technology, combined with drug patch product solutions, to licensing partners in a one stop shop concept.

Dr. Christof Boehler, Pantec Biosolutions CEO, said: “We are proud to be presenting our novel P.L.E.A.S.E ® platform for the first time to our potential licensing partners. After just three years of development, we are now in the position to showcase the hand held device and to unveil promising preclinical data”.

Commenting on the development of the device, Pantec Biosolutions CTO, Thomas Bragagna, said: 'In order to achieve such a task within three years, our team developed a second to none interdisciplinary approach to create a system that is as simple as it is high-tech. We have designed a drug delivery device which is convenient and safe to use for both medical professionals and patients”.

– ends –

For further details please contact:

Media relations

Tristan Jervis, Account Director
Justine Lamond Account Manager
Tel: +44 (0) 20 7457 7857

At the Company

Pantec Biosolutions AG
Dr. Christof Boehler, Chief Executive Officer
Tel: +423 377 1390

About Pantec Biosolutions and P.L.E.A.S.E. ®

Pantec Biosolutions is a private drug delivery company specialising in laser microporation technology to deliver large molecular weight drugs into the epidermis for systemic or topical uptake, removing unwanted therapeutic side effects including drug degradation. Its proprietary P.L.E.A.S.E.® (Painless Laser Epidermal System) platform enables efficient, needle free and painless application of biopharmaceutical drugs, such as IVF hormones, in varying and individualised dosages through partnered patch technology.

The Company’s P.L.E.A.S.E.® platform is available both for the development of the Company’s own pipeline and for penetration into new markets through strategic partnerships. The technology is currently in clinical trials for the delivery of IVF hormone therapy, a market with an estimated value of US$1.5 – 2 billion.

Pantec Biosolutions is based in Ruggell, Liechtenstein.

More information on Pantec Biosolutions can be found at

Publisher Contact Information:

Pantec Biosolutions
+423 377 1390

Company profile of Pantec Biosolutions
Past press releases of Pantec Biosolutions.


Tech investments
From our Online Data Service
VC-backed companies
From our Radar

Recent Deals

Nov 25€24.0MInternet commerce
Nov 8N/AOther Computers & Electronics
Nov 5€2.1MAudio/Video
Nov 5€5.2MOther Computers & Electronics
Nov 5€0.4MInternet services
Nov 5€1.3MSecurity
Nov 5€1.5MAudio/Video

For information on Europe's most extensive database on technology funding click here!


Press Releases

Sep 30
tetavi raises $6 million to help more companies bring 3d holograms ...

May 28
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
nethone raised over $1 million from innovation nest

Mar 31
the fit allocates chf 100'000 to comppair technologies

Jan 29
yumpingo raises $10m to transform guest experiences in restaurants

About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.